Bristol Myers Squibb Co. has identified molecular glue degraders comprising cereblon ligands and a eukaryotic peptide chain release factor GTP-binding subunit ERF3A (GSPT1)-targeting moiety acting as GSPT1 degradation inducers reported to be useful for the treatment of cancer.
Scientists at ETH Zürich, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized fluorescent probes acting as monoglyceride lipase (MGLL; MAGL) inhibitors reported to be useful for diagnostic imaging of MAGL.
Legislators in Washington again are considering a pair of bills that would affect how patents are obtained and sustained including the Patent Eligibility Restoration Act of 2025. This would constitute a big win for companies in the life sciences thanks to provisions that clarify just what is and is not eligible for patent protection.
Few observers think of CPAP machines as common fare where the med-tech patent wars are concerned, but Resmed Corp. recently came away with a win in litigation that resulted in the nullification of the first 20 claims of a CPAP patent held by Cleveland Medical Inc.
Canwell Biotech Ltd. has described tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer.
Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.
Korea Research Institute of Chemical Technology has identified glutaminase inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Researchers at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have synthesized interleukin-17A (IL-17A) inhibitors reported to be useful for the treatment of inflammatory disorders.
Scientists at Arontier Co. Ltd. and Korea Research Institute of Chemical Technology have disclosed ectonucleotide pyrophosphatase/phosphodiesterase 2 (ENPP2; autotaxin) inhibitors reported to be useful for the treatment of hepatic steatosis, hepatic fibrosis, cirrhosis, liver failure, hepatitis and liver cancer, among others.
RSS
